Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

WALTHAM, Mass., September 14, 2021 /PRNewswire/ — Skyhawk Therapeutics, Inc. today announced that Fidelity Management & Research Company LLC has led a $133 million oversubscribed investment round in Skyhawk, along with other major investors. This brings total equity funding plus partnership capital in the Company to over $600 million thus far, with potential future milestones of over $20 billion plus ongoing royalties.

“This investment round strengthens Skyhawk’s capacity to advance our internal pipeline of drug candidates deep into the clinic,” said Bill Haney, co-founder and CEO of Skyhawk Therapeutics. “We are delighted that investors support our novel platform, a strong foundation from which to advance a series of our internal drugs for patients, even as we expand our work making drug candidates for our pharma collaborators.”http://www.skyhawktx.com, https://twitter.com/Skyhawk_Tx , https://www.linkedin.com/company/skyhawk-therapeutics/

Endpoints article, here: https://endpts.com/bill-haney-adds-another-133m-to-skyhawks-coffers-as-the-rna-startup-guns-for-the-clinic/